Pfizer and BioNTech would now seek regulatory approval for the third dose of its Covid-19 vaccine. The interim trial data showed that a third dose can push the antibodies five to 10 times higher against the said variants of the coronavirus as compared to the first two doses.
Also Read | Union Cabinet Expansion 2021: Here’s official list of Council Of Ministers; Who’s got what?
This will also provide better protection than the current procedure of administering two shots, the companies stated.
The development comes after several reports stated that the vaccine was less effective against the Delta variant of the SARS-CoV-2 virus.
A study, published in the journal 'Nature', stated that a single shot of the Pfizer-BioNTech vaccine, or even the AstraZeneca, "barely" induces any neutralizing antibodies against the Delta variant.
In view of these studies, Pfizer-BioNTech announced that they were working on a Delta-specific vaccine.
-PTC News